{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:22:49Z","timestamp":1792135369762,"version":"4.4.0"},"reference-count":59,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4521,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1999,9]]},"abstract":"<jats:p>We conducted a systematic review, with MEDLINE and Cochrane Library data base searches and bibliographic reviews, of English\u2010language reports describing therapy with low\u2010molecular\u2010weight heparin (LMWH) in pregnancy. Altogether 40 citations, excluding abstracts, were identified. When the quality of evidence was categorized according to the method outlined by the U.S. Preventive Services Task Force, 2 articles were level I, 3 were level II\u20101, 3 were level II\u20102, 4 were level II\u20103, 9 were level III, and the remaining 19 were classified as other (i.e., below level III). Of the 728 pregnant women and 1 postpartum woman described in the 40 citations, 340 (47%) received dalteparin, 192 (26%) enoxaparin, 108 (15%) certoparin, 54 (7%) nadroparin, 30 (4%) other LMWH, and 6 (&lt; 1%) unspecified. The indication for LMWH in most patients (606 pregnancies, 83%) was for thromboprophylaxis. Daily doses ranged from 2500\u201322,000 U for dalteparin, 20 mg (2000 U)\u201380 mg (8000 U) for enoxaparin, 3000 U for certoparin, and 2050\u201315,000 U for nadroparin. Regimens included fixed dosages, increasing dosages as pregnancy progressed, dosages based on body weight, and dosages titrated according to anti\u2010Xa levels. Duration of therapy ranged from a single dose to 476 days. Maternal anti\u2010Xa levels were reported for 255 pregnancies. Target anti\u2010Xa levels ranged from 0.1\u20130.6 U\/ml and measured values from 0.0\u20130.7 U\/ml. Major maternal findings were 18 local and generalized skin reactions, 27 bleeding complications, 9 thromboembolic events, 8 deep vein thromboses, 1 bilateral renal vein thrombosis, 4 pulmonary emboli, 1 hepatic infarction, 4 cases of thrombophlebitis, 12 cases of preeclampsia, 1 placental abruption, and 2 osteoporotic vertebral fractures. A major fetal finding was lack of anti\u2010Xa activity in fetal or cord blood. Published experience suggests that LMWHs are generally safe and effective when administered for thromboprophylaxis during pregnancy. Until prospective, randomized, controlled trials comparing them with unfractionated heparin are performed, their benefits in pregnancy will remain inconclusive.<\/jats:p>","DOI":"10.1592\/phco.19.13.1013.31588","type":"journal-article","created":{"date-parts":[[2004,5,7]],"date-time":"2004-05-07T06:14:36Z","timestamp":1083910476000},"page":"1013-1025","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Low\u2010Molecular\u2010Weight Heparins in Pregnancy"],"prefix":"10.1002","volume":"19","author":[{"given":"Mary H. H.","family":"Ensom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary D.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.489S"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.5_Supplement.524S"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0038-1649639","article-title":"Comparison of the nonspecific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins","volume":"70","author":"Young E.","year":"1993","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-0038-1642434","article-title":"Ex\u2010vivo and in\u2010vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin","volume":"71","author":"Young E.","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_6_2","first-page":"5","article-title":"Randomized trial of a low\u2010molecular\u2010weight heparin (Kabi 2165) versus adjusted dose subcutaneous standard heparin in the prophylaxis of deep\u2010vein thrombosis after elective hip surgery","volume":"1","author":"Dechavanne M.","year":"1989","journal-title":"Haemostasis"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-7-545"},{"issue":"3","key":"e_1_2_1_8_2","first-page":"284","article-title":"Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: a meta\u2010analysis","volume":"17","author":"Lassen MR","year":"1991","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93223-A"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00443477"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-11-199312010-00008"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/archinte.1993.00410190057007","article-title":"Prophylactic agents for venous thrombosis in elective hip surgery","volume":"153","author":"Mohr DN","year":"1993","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510460072036"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb07540.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1055\/s-0038-1642546","article-title":"Thrombosis prophylaxis in an AT III deficient woman: application of a low molecular weight heparinoid [letter]","volume":"55","author":"Henny CP","year":"1986","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-0038-1646545","article-title":"Low molecular weight heparin treatment in a pregnant woman with allergy to standard heparins and heparinoid [letter]","volume":"61","author":"Boer K.","year":"1989","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-0038-1648403","article-title":"Absence of transplacental passage of Fragmin (Kabi) during the second and third trimesters of pregnancy [letter]","volume":"67","author":"Forestier F.","year":"1992","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.47.1.94-c"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04854.x"},{"key":"e_1_2_1_20_2","first-page":"55","article-title":"Low molecular weight heparin as thromboprophylaxis in pregnancy [letter[","volume":"24","author":"Wahlberg TB","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_1_21_2","first-page":"124","article-title":"Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy [letter]","volume":"76","author":"Boda Z.","year":"1996","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_22_2","first-page":"627","article-title":"Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacement [letter]","volume":"76","author":"Lee LH","year":"1996","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(97)70134-0"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60394-7"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03080.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(93)90127-A"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1055\/s-0038-1642516","article-title":"High\u2010dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome","volume":"71","author":"Arnout J.","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90047-0"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199510000-00008"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(95)02425-C"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1996.tb09919.x"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440280157015"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00105-1"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.1997.tb00832.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/000992289803700607"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(92)90261-G"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(94)90351-4"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0029-7844(95)00452-1"},{"key":"e_1_2_1_39_2","first-page":"131","article-title":"A study of sixty pregnancies in patients with the antiphospholipid syndrome","volume":"14","author":"Lima F.","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(97)70403-4"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(97)00110-3"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1992.tb00795.x"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1994.tb13014.x"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(98)00083-9"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600606"},{"key":"e_1_2_1_46_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-0038-1655903","article-title":"Thrombo\u2010prophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies","volume":"77","author":"Hunt B.","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_47_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0038-1653781","article-title":"Use of a low\u2010molecular weight heparin (enoxaparin) or of a phenformin\u2010like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity","volume":"73","author":"Gris J\u2010C","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_48_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-0038-1646526","article-title":"Low molecular weight heparin Novo (LHN\u20101) does not cross the placenta during the second trimester of pregnancy","volume":"61","author":"Omri A.","year":"1989","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1055\/s-0038-1646338","article-title":"Use of low molecular weight heparin in pregnancy","volume":"68","author":"Melissari E.","year":"1992","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/0301-2115(95)02358-5"},{"key":"e_1_2_1_51_2","first-page":"314","article-title":"Lack of anti\u2010factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women","volume":"23","author":"Harenberg J.","year":"1993","journal-title":"Haemostasis"},{"key":"e_1_2_1_52_2","first-page":"1","article-title":"Thromboprophylaxis with low molecular mass heparin, \u201cFragmin\u201d (dalteparin), during pregnancy\u2014a longitudinal safety study","volume":"9","author":"Blomback M.","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199806000-00006"},{"key":"e_1_2_1_54_2","first-page":"861","volume-title":"Guide to preventive services","author":"U.S. Preventive Services Task Force","year":"1996"},{"key":"e_1_2_1_55_2","first-page":"734","article-title":"Transfer of low molecular weight heparin during breast feeding [abstr]","volume":"78","author":"Richter C.","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(91)90224-9"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806113382415"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806113382415"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(93)90378-V"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3552(97)80024-7"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.19.13.1013.31588","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.19.13.1013.31588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:29:52Z","timestamp":1761064192000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.19.13.1013.31588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,9]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1999,9]]}},"alternative-id":["10.1592\/phco.19.13.1013.31588"],"URL":"https:\/\/doi.org\/10.1592\/phco.19.13.1013.31588","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,9]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}